Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series

Gisondi, Paolo; Mattiucci, Alessandra; Tonin, Beatrice; Girolomoni, Giampiero

doi:10.1111/jdv.15518

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, retinoids were also widely used for the experiments of diverse human cancers due to their influences on the cell proliferation and apoptosis of multiple tumor cells . Currently, the commonly used retinoids were all‐trans‐retinoic acid (ATRA), acitretin, isotretinoin, and tazarotene . However, repeated and long‐term use of these drugs often caused a lot of adverse reactions like allergic reaction, dry skin, piercing, photosensitivity, and skin infection.…”

Section: Introductionmentioning

confidence: 99%

The third‐generation retinoid adapalene triggered DNA damage to induce S‐phase arrest in HaCat cells

Wang

et al. 2019

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Epidermal proliferative diseases consisted of a series of common skin diseases, most of which were recurrent chronic skin diseases, and had greatly negative influence on the life quality of patient. Retinoids exhibited vital roles in the treatment of many skin diseases. Our recent study demonstrated that adapalene significantly inhibited the growth of HaCat cells, and the inhibitory activity was stronger than other retinoids, such as all-trans-retinoic acid, acitretin, isotretinoin, tazarotene, and bexarotene. Further study showed that adapalene suppressed the colony formation of HaCat cells, and it dramatically triggered S-phase arrest and apoptosis, rather than G1 phase arrest which was reported in other retinoids in several studies. Additionally, adapalene treatment greatly upregulated the protein expression of DNA damage marker c-H2AX, which was in accord with the results of the elongation of tail moment by comet electrophoresis analysis. Moreover, DNA damage was triggered and DNA repair was suppressed synchronously with adapalene treatment, which accounted for the mechanism of S-phase arrest induced by adapalene. In summary, our recent work demonstrated that adapalene showed strong antiproliferation activity in HaCat cells and could be an alternative agent for the epidermal proliferative disease. I N T R O D U C T I O NEpidermal proliferative diseases were a large class of dermatosis which contained various common and uncommon skin diseases such as psoriasis, verruca vulgaris, pityriasis rubra pilaris, and palmoplantar keratoderma. Moreover, most of the epidermal proliferative diseases were recurrent chronic skin diseases which seriously affected the life quality of patients. Long-term clinical practice showed that oral or topical retinoids were a kind of effective and relatively safe therapy for these diseases. Retinoids were a serious of natural or synthetic derivatives of retinol which played vital roles in the differentiation and proliferation of epidermal cells, and made great influence on the formation, development and maintenance of normal epidermis. In addition, retinoids were also widely used for the experiments of diverse human cancers due to their influences on the cell proliferation and apoptosis of multiple tumor cells [1]. Currently, the commonly used retinoids were alltrans-retinoic acid (ATRA), acitretin, isotretinoin, and tazarotene [2][3][4][5][6][7][8]. However, repeated and long-term use of these drugs often caused a lot of adverse reactions like allergic reaction, dry skin, piercing, photosensitivity, and skin infection. More importantly, the teratogenicity of retinoids could not be ignored. Hence, the high-efficiency and low-adverse-reaction drugs remained the pursuit of the clinical application.Adapalene, the third-generation synthetic retinoic acid, was hardly absorbed into blood circulation and ª 2019 Soci et e Franc ßaise de Pharmacologie et de Th erapeutique 380

show abstract

Section: Introductionmentioning

confidence: 99%

The third‐generation retinoid adapalene triggered DNA damage to induce S‐phase arrest in HaCat cells

Wang

et al. 2019

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…1 Despite the limited extension of this condition, PPP is able to produce a relevant functional and social disability. 1 Currently several biological treatments, in addition to first lines therapies like retinoids, methotrexate, or small molecules, 2 have been suggested as effective options. Anti-tumor necrosis factor-alfa and anti-interleukin (IL)-17 inhibitors demonstrated a great efficacy, respectively, for hyperkeratotic PPP and pustular PPP treatment.…”

mentioning

confidence: 99%

Dimethylfumarate efficacy and safety in palmoplantar psoriasis patient affected by hepatitis b and depression: A case report

Mazzilli

Cosio

Botti

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study

Hassanandani¹,

Panda²,

Jena³

et al. 2022

IJDVL

View full text Add to dashboard Cite

Background Palmoplantar psoriasis is a chronic debilitating condition which significantly impairs quality of life. Objectives To assess the efficacy and safety of the combination of apremilast and methotrexate compared with methotrexate monotherapy in the treatment of palmoplantar psoriasis. Also, to study the impact on treatment on the Dermatology Life Quality Index and Palmoplantar Quality of Life Index. Methods A total of 64 patients were randomised to two groups in a 1:1 ratio - Group A received both methotrexate and apremilast in combination, while Group B received only methotrexate, for 16 weeks. The primary endpoints were the mean score of Modified Palmoplantar Psoriasis Area and Severity Index at week 16, the proportion of patients achieving modified palmoplantar psoriasis area severity index-75 and/or Palmoplantar Psoriasis Physician Global Assessment score 0/1 at week 16. Results A significantly higher proportion of patients in Group A achieved Modified Palmoplantar Psoriasis Area and Severity Index-75 at week 16 (43% in Group A vs 30% in Group B). The Modified Palmoplantar Psoriasis Area and Severity Index score was significantly lower in the combination group at week 16 (4.03 ± 2.05 in Group A and 5.89 ± 2.31 in Group B, P-value = 0.002). About 80% of patients in the combination group with baseline Palmoplantar Psoriasis Physician Global Assessment ≥3 achieved Palmoplantar Psoriasis Physician Global Assessment 0/1 compared to 60% in Group B. The combination group showed a significantly higher reduction in Dermatology Life Quality Index and Palmoplantar Quality of Life Index scores compared to the methotrexate alone group (P-value = 0.025). No notable adverse events were observed. Limitation The limitations of the study were single blinding, small sample size and a lack of longer follow up to assess the rate of relapse. We did not account for attrition during sample size calculation. Also, due to the paucity of data regarding the use of apremilast in palmoplantar psoriasis, definitive comparisons could not be made with previous studies. Conclusion The combination of apremilast and methotrexate has superior efficacy and a similar safety profile as compared to methotrexate monotherapy for the treatment of moderate to severe palmoplantar psoriasis.

show abstract

Low dose acitretin versus methotrexate in the treatment of palmoplantar psoriasis: a case series

Cited by 3 publications

References 7 publications

The third‐generation retinoid adapalene triggered DNA damage to induce S‐phase arrest in HaCat cells

The third‐generation retinoid adapalene triggered DNA damage to induce S‐phase arrest in HaCat cells

Dimethylfumarate efficacy and safety in palmoplantar psoriasis patient affected by hepatitis b and depression: A case report

Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study

Contact Info

Product

Resources

About